Introduction
The hepatocyte growth factor/scatter factor (HGF/SF) receptor, Met, is involved in the regulation of mitogenesis, cell motility, cell morphology and expression of speci®c genes in endothelial and epithelial cells after treatment with its ligand HGF/SF (Gherardi and Stoker, 1991) . The ligand is a heparin-binding protein and is produced by cells of mesodermal origin, such as ®broblasts (Nakamura et al., 1989; Naldini et al., 1991) . Met is a 190 kD protein identi®ed as a high anity receptor for HGF/SF in an epithelial tumor cell line (GTL16) . The receptor for HGF/SF was identi®ed as the normal counterpart of an oncogene, Tpr-Met, that arose in cell culture, by a spontaneous chromosomal translocation after treatment with a carcinogen (Park et al., 1986; Cooper et al., 1984) . In Tpr-Met, the leucine-zipper dimerization domain of the nuclear envelope protein Tpr (Byrd et al., 1994 ) is linked to the intracellular moiety of the HGF/SF receptor, Met, containing the tyrosine kinase domain (reviewed in Comoglio, 1993) . Thus, while Met dimerizes and becomes active as a signal transducer upon ligand binding, Tpr-Met spontaneously dimerizes through the leucine-zipper domain of Tpr, in the absence of the ligand, and is constitutively active (Rodrigues and Park, 1993) .
Upon ligand-binding and consequent dimerization of Met, ®ve tyrosine residues in the intracellular region become phosphorylated: two inside and three outside the kinase domain (see Figure 2) (Ponzetto et al., 1993; Ferracini et al., 1991) . The two tyrosine residues in the kinase domain, Y 1234 and Y
1235
, together with Y
1230
, are part of a`three-tyrosine' motif found in other tyrosine kinase receptors (Hanks et al., 1988) . The phosphorylation of Y 1234 and Y 1235 is responsible for positive regulation of the kinase activity (Longati et al., 1994) . Two of the three phosphorylated tyrosine residues in the C-terminus region outside the kinase domain, Y 1349 and Y
1356
, have been found to be responsible for the binding of several signaling molecules, GRB2, SHC, phosphatidylinositol 3-kinase (PI 3-kinase), phospholipase C g (PLCg) and pp60 c-src Bardelli et al., 1992) . All of these signaling molecules bind via their respective SH2 domains (reviewed in Schlessinger, 1994) . Binding of PI 3-kinase to the receptor has been demonstrated, although no typical PI 3-kinase binding sequence (YMXM) is found in Met (see Figure 2) (Ponzetto et al., 1993) and reviewed in Varticovski et al. (1994) .
In this study, we have found that Tpr-Met oncogene can induce the urokinase-type plasminogen activator (uPA) promoter vai a Ras-dependent pathway, like FGF-2 and 12-O-tetradecanoylphorbol 13-acetate (TPA) (Besser et al., 1995a) and middle-T (Besser et al., 1995b) . Regulation of the uPA gene by Met is of special interest because Met is involved in tumor metastasis (Di Renzo et al., 1994; Comoglio, 1993) , a process in which uPA has been strongly implicated (Dano et al., 1985) . It has been shown that uPA activity is induced by HGF/SF treatment of MDCK cells (Pepper et al., 1992) , SK-LMS-1 cells (Jeers et al., 1996) and of the highly liver-metastatic LS9 but not of the low liver-metastatic F1 B16 melanoma cells (Rusciano et al., 1995) . Moreover, uPA mRNA is induced by HGF/SF treatment in A549 lung carcinoma cells (Boccaccio et al, 1994) . Interestingly, uPA is also involved in the extracellular activation of HGF/SF (Naldini et al., 1992) , suggesting a feedforward loop for HGF/SF expression.
uPA is a secreted serine protease which converts the ubiquitous zymogen plasminogen to plasmin, a trypsinlike serine protease with wide substrate speci®city. Through interaction with a speci®c uPA receptor on the cell surface and subsequent generation of active plasmin, uPA plays an important role in cellassociated proteolytic processes such as tissue remodeling during development, cell migration during wound healing, angiogenesis, gametogenesis and tumor metastasis (reviewed in Kwaan, 1992; Blasi and Verde, 1990; Dano et al., 1985; Tienari et al., 1991) . uPA is also involved in the activation of dierent growth factors converting the inactive precursor to the active molecule, as has been reported for HGF/SF and tumor growth factor-b (Naldini et al., 1992; Sato et al., 1990) . Re¯ecting its wide range of biological activity, uPA is expressed by a large number of cell types and its expression is controlled by a variety of extracellular signals depending on cell type (reviewed in Dano et al., 1985) . The regulation of uPA gene expression by TPA (Lee et al., 1993; Nerlov et al., 1992; Degen et al., 1985) , cAMP (Lee et al., 1994a; Menoud et al., 1993a; von der Ahe et al., 1990a) , cytoskeletal reorganization (Botteri et al., 1990; Lee et al., 1993) , the protein phosphatases 1/2A inhibitor okadaic acid (Lee et al., 1994b; Nagamine and Ziegler, 1991b) and FGF-2 (Besser et al., 1995a; Gualandris and Presta, 1995a; Tienari et al., 1991) has been extensively studied. In addition, the uPA gene is activated by a variety of other inducers Dano et al., 1985) .
In the present work, we investigated the eect of the wild type and dierent mutants of Tpr-Met on the induction of the uPA gene promoter in NIH3T3 ®broblasts and the signaling pathways involved in uPA regulation.
Results
Involvement of SOS, Ras, Raf-1 and ERK proteins in uPA gene regulation by Tpr-Met Previously, we showed that FGF-2 and TPA induce uPA gene expression via a pathway involving Ras, ERK and AP1 (Besser et al., 1995a) . To determine whether Tpr-Met, the activated form of the HGF/SF receptor (c-Met), can also activate the uPA gene via a similar pathway, we performed transient transfection assays using a luciferase expression system. A luciferase construct containing 8.2 kb of the murine uPA promoter (pGL2muPA-8.2) was induced 10-and 25-fold by coexpression of Tpr-Met in MDCK ( Figure 1a ) and NIH3T3 (Figure 1b ) cells, respectively.
We cotransfected wild-type forms and dominant negative mutants of SOS, H-Ras and Raf-1 and wildtype MKP-1, a dual-speci®city protein phosphatase known to dephosphorylate and inactivate ERK-1 and ERK-2 (Sun et al., 1993) , together with pGL2muPA-8.2 with or without Tpr-Met into MDCK (Figure 1a ) or NIH3T3 cells (Figure 1b) . The high uPA promoter activity induced by Tpr-Met was strongly suppressed by dominant negative mutants of SOS, Ras, Raf-1 and by wild-type MKP-1 in both cell lines. These results suggest that Tpr-Met activates a pathway involving SOS, Ras, Raf-1 and ERK. To prove that the inhibition was due to the dominant negative nature of the mutants and not to a non-speci®c eect, the experiments were carried out in parallel with the corresponding wild type proteins as controls. Not only the wild type forms of these molecules did not inhibit, but actually they increased the level of both the basal and induced activity of the uPA promoter in MDCK cells. In NIH3T3 cells, wild-type SOS and Raf-1 had a much higher enhancing eect than Ras. This may be due to lower expression of the Ras protein or it could indicate that Grb2 or SOS may be present in these cells in limiting amounts with respect to downstream members of the signaling cascade.
Like TPA, FGF-2 (Besser et al., 1995a) , and polyomavirus middle-T (Besser et al., 1995b) , TprMet induces the uPA promoter via a PEA3/AP1 element at 72.4 kb and an element between 78.2 and 76.6 kb with respect to the transcription initiation 
Tpr-Met activates the uPA promoter in a dose-dependent manner
The results of the previous experiment suggest that multiple signaling molecules may interact with Tpr-Met to mediate its ability to fully induce the uPA gene promoter. Increased receptor concentrations may perturb the stoichiometry of multiple-component interaction on the receptor, and thereby aect the ensuring signaling. To test this possibility, we performed dose-response experiments using dierent Figure 3b shows that for the wild type and Y1356F, optimal induction was obtained with 30 ng of expression vector. A further increase in DNA concentration reduced the induction and this was more prominent with wild-type Tpr-Met. The reduction at high vector concentrations is not due to a non-speci®c eect of high amounts of DNA, because 300 ng of the empty vector pMT2 produced no inhibitory eect when added to 30 ng of the wild type Tpr-Met vector (Figure 3c ). On the contrary, the vector for Y1349-1356F, which has only one phosphorylated tyrosine residue (Y1365) for which no binding proteins have been identi®ed and is capable of only modest induction, gave a monophasic dose-response curve. The very low inductive activity of the vector for Y1349-1356-1365F, which has no docking sites, was already saturated at 3 ng. The kinase-inactive mutant lys-, which has a K-to-R mutation in the ATP binding site, showed no induction at any concentration. These results showing biphasic dose response curves with receptors that contain more than one docking sites corroborate our hypothesis that full signal transducing activity of Met receptor requires the concomitant interaction with multiple signaling molecules on a single receptor molecule, a condition dicult to attain at high receptor concentrations. It should be noted that the levels of phosphorylated Tpr-Met protein necessary to elicit an inhibitory eect are probably unique to our arti®cial system (NIH3T3 cells transfected with a constitutively active Tpr-Met kinase), and unlikely to occur in the case of tumors either over-expressing the full size receptor or containing an autocrine loop. In fact it has been recently shown that establishment of an autocrine loop actually upregulates the protein levels of both uPA and its receptor in sarcoma cells expressing high levels of c-Met (Jeers et al., 1996) .
PI 3-kinase is involved in the activation of the uPA gene promoter
It has been shown that PI 3-kinase interacts with TprMet in vitro (Ponzetto et al., 1993) . To evaluate the role of PI 3-kinase, which binds both Y 1349 and Y 1356 in Tpr-Met (Ponzetto et al., 1993) , we mutated either one or both of these sites to consensus sites for PI 3-kinase (1349MPM or 1349MPM-1356MDM, Figure 4 ), or both sites to consensus GRB2 sites (H1351N). Mutation of Y 1349 to a PI 3-kinase site (1349MPM) or to another GRB2 site (H1351N) showed no or slightly positive eects, respectively. The result suggests that as long as one GRB2 site is present, the other site can be an optimal PI 3-kinase or GRB2 site without in¯uencing uPA gene induction (Figure 4a ). When both sites were converted to PI 3-kinase binding sites, the induction was reduced to 27% of the control, suggesting that PI 3-kinase alone is able to convey signals and induce the uPA gene, albeit at a lower level compared to control.
To further examine the role of PI 3-kinase, we tested the eects of overexpression of the wild type (p85), and the dominant negative (pD85) and C-terminal-truncated (pDC85) mutants of the p85 regulatory subunit of PI 3-kinase on the induction of the uPA promoter by wild type Tpr-Met (Figure 4b ). In pD85, a region between the two SH2 domains is deleted so that it does not bind p110 PI 3-kinase catalytic subunit. In pDC85, the C-terminal region of the protein is deleted so that the molecule loses the ability to bind phosphotyrosine residues and to bind to the catalytic subunit p110 (Stephens et al., 1993) . As shown in Figure 4b , not only pD85 but also the wild type pD85 blocked the induction of the uPA promoter by Tpr-Met. The induction by 1349MPM-1356MDM, which contains two consensus PI 3-kinase sites, was also blocked by the wild type and the dominant negative p85 (data not shown). The inhibition required the binding of the receptor to the SH2 domains of p85, because the induction by Tpr-Met was not aected by pDC85. This inhibition was not a non-speci®c eect of these molecules on gene expression because SV40 promoter-driven luciferase expression was not modulated by neither p85 or pD85 (Figure 4b ). pDC85 showed positive eects on the basal expression of the uPA promoter, but this is a non-speci®c eect because the SV40 promoter-driven luciferase gene expression was also upregulated (pGL2control; Figure 4b ). To examine the speci®city of the eects of p85, we measured its eect on other inducers of the uPA promoter, namely constitutively active v-Src and Ras 61L (Figure 4c ). Both p85 and pD85 reduced v-Src and Ras 61L induction, and completely suppressed the basal and Tpr-Met-induced expression. The repressing eects of p85 and pD85 on v-Src induction were stronger than on Ras 61L induction, and p85 appeared to have a stronger eect on both inductions than pD85. These results suggest that the direct binding of p85 to Tpr-Met leads to a full blockage of Tpr-Met induction, and furthermore, that PI 3-kinase activity is also required downstream of Ras for the induction of the uPA promoter.
Discussion
We studied the induction of the uPA promoter by TprMet in MDCK and NIH3T3 cells, and elucidated the signaling pathway evoked by Tpr-Met which leads to Ras-dependent gene regulation. Overexpression of various dominant negative molecules revealed that a signaling pathway involving SOS, Ras, Raf-1 and ERK is implicated in the activation of the uPA promoter by Tpr-Met in NIH3T3 and MDCK cells (Figure 1) .
The Tpr-Met receptor provides an interesting model system to study the signaling pathways because of its unique structure: the receptor contains two tyrosine residues outside the tyrosine kinase domain which have been shown to be recognized by SH2 domains of various downstream signaling molecules, i.e. GRB2, PI 3-kinase, c-Src, PLC-g and SHC . Analysis of dierent forms of Tpr-Met with mutations in these multifunctional docking sites (Figure 2 ) revealed the involvement of GRB2 in the induction; mutation of the tyrosine at residue 1356 to phenylalanine (Y1356F) or of the asparagine at residue 1358 to histidine (N1358H), which destroy the GRB2 binding site, strongly reduced uPA promoter induction ( Figure  3a ). However, a substantial level of activation of the uPA promoter was observed with both mutant receptors; the induction was blocked only when positions 1349 and 1356, were both changed to phenylalanine (Figure 3a) . A requirement for the stimultaneous binding of multiple signaling molecules on the receptor is suggested from the results of doseresponse experiments with expression vectors for dierent Tpr-Met mutants (Figure 3b ). The wild type, which contains more than one docking sites, showed a sharp biphasic dose-response curve, suggesting that full signal transducing activity of the Met receptor requires the concomitant interaction of multiple signaling molecules with a single receptor molecule, a condition dicult to attain at high receptor concentrations. These results suggest that signaling molecules other than GRB2 are capable of relaying activation signals of the receptor to the uPA promoter and that they may cooperate with GRB2 in the induction.
PI 3-kinase seems to be one of these cooperating signaling molecules. A mutant receptor, in which both SH2-binding sequences were mutated to consensus sites for PI 3-kinase, 1349-YMPM and 1356-YMDM (Songyang et al., 1993; Ponzetto et al., 1993) , showed reduced but signi®cant levels of activation of the uPA promoter (Figure 4a ) comparable to other mutants with impaired GRB2 binding (Y1358F and N1358H, Figure 3a) . Coexpression of wild-type or dominant negative p85 had blocking eects on the induction, whereas a p85 mutant with a truncation at the Cterminus, which lost the ability to bind to Tpr-Met, had no or only a slightly positive eect (Figure 4b ). This result suggests that the dominant negative p85 could inhibit the induction by blocking the binding sites in Tpr-Met for the endogenous p85, whereas overexpression of wild type p85 titrates out its endogenous partner, the p110 catalytic subunit. It has been shown that p85 and p110 subunits make a complex before receptor binding (Stephens et al., 1993) . Similarly, expression of wild type or dominant negative p85 had a strong negative eect on the activation of PI 3-kinase (Rameh et al., 1995) and p70 S6 kinase (XF Ming, personal communication) by PDGF treatment and on the induction of the uPA promoter by middle-T (M Urich, personal communication). Inhibitory eects of p85 and pD85 are dependent on their interaction with Tpr-Met, because the inhibition was not observed with the SV40 promoter which was independent of Tpr-Met-induced signaling and pD85 which does not bind to Tpr-Met showed no eect ( Figure 4b) . Interestingly, the induction of uPA promoter by v-Src and Ras61L was also inhibited by overexpression of p85 and pD85 (Figure 4c ), suggesting that Ras-dependent signaling pathway requires the presence of active PI 3-kinase at downstream of Ras or parallel to Ras-dependent signaling to induce gene expression. In this context, it is noteworthy that Rasmediated activation and nuclear translocation of ERK1 also requires PI 3-kinase mediated signals (Urich et al., 1995) . Feeding of the signal of PI 3-kinase activation to the ERK-dependent pathway between Ras and Raf-1 has also been suggested by Cross et al. (1994) .
Both HGF/SF and uPA expression have been implicated in malignant tumor formation (reviewed in Dano et al., 1985; Di Renzo et al., 1994; Comoglio, 1993) . Several studies have suggested a causal relationship between these two factors in the context of malignant tumor formation. Pepper et al. (1992) showed that HGF/SF induces morphogenic changes in MDCK cells by increasing both uPA and cell surface uPA receptor levels. More recently, Jeers et al. (1996) have shown that the activation of an HGF*Met signaling circuit in sarcoma cells results in enhanced tumorigenesis and metastasis, concomitant with elevated levels of cell-associated uPA and plasmin-generating ability of these cells. A functional interaction has also been suggested; Naldini et al. (1992) have shown that uPA acts directly on pro-HGF/SF and converts it to active, mature HGF/SF. Thus, the two molecules may consolidate HGFdependent biological processes via positive feedback regulation of each other at dierent levels of their expression.
In conclusion, the results of this study show the key role of GRB2 in Tpr-Met-induced activation of the uPA promoter but also underline the importance of the tightly controlled interplay of dierent signaling molecules on the HGF/SF receptor for optimal induction of the pathways leading to the activation of ERK-dependent gene regulation. Further experiments will elucidate the exact function of PI 3-kinase and the uPA gene regulation by Tpr-Met D Besser et al involvement of other signaling molecules, e.g. PLCg or SHC, in the activation of the ERK-pathway by TprMet and other inducers.
Materials and methods

Cell culture
Madine Darby canine kidney (MDCK) cells were cultured in Dulbecco's modi®ed Eagle medium (DMEM; Gibco Diagnostics) supplemented with 10% fetal calf serum (FCS; Gibco Diagnostics). NIH3T3 ®broblasts were cultured in DMEM supplemented with 10% calf serum (CS; Gibco Diagnostics). The medium contained 0.2 mg/ml streptomycin and 50 U/ml penicillin in a humidi®ed atmosphere at 378C with 5% CO 2 .
Plasmids
The plasmid pGL2muPA-8.2 was constructed by inserting the murine uPA gene promoter (from 78.2 kg to +398 bp with respect to the transcription initiation site) (Cassady et al., 1991 , and unpublished sequence) upstream of the luciferase-coding region of the promoter-less plasmid pGL2-basic (Promega). In the plasmid p36AP1-tk-Luc (constructed by E Ser¯ing and provided by R SchuÈ le), three consensus AP1 elements are inserted upstream of the minimal promoter of the thymidine kinase gene (746 to +52) containing the TATA box and the transcription initiation site, which is linked to the luciferase gene. The plasmid pGL2 control containing the SV40 early promoter and enhancer was obtained from Promega.
The following expression vectors were used: cloning of pMT2-tpr-met was described earlier ; mutants of Tpr-Met pMT2-tpr-met/H1351N, pMT2-tpr-met/ Y1349F, pMT2-tpr-met/Y1356F, pMT2-tpr-met/N1358H, pMT2-tpr-met/Y1365F, pMT2-tpr-met/Y1349-1356F or pMT2-tpr-met/Y1349-1356-1365F, pMT2-tpr-met/lys-were prepared according to the method previously described . pSRa-mSOS1 and pSRa-DmSOS1 contain coding regions of wild-type and dominant negative forms of SOS, respectively, linked to the HTLV1-LTR promoter (Sakaue et al., 1995) . pMuLV-Ha-ras expressing wild type Ras, pRSV H17 expressing dominant negative Ras Asn17 and pRSV Leu61 expressing constitutively active Ras Leu61 (de Vries-Smits et al., 1992) were provided by JL Bos (Utrecht). pc-raf-1 and pCMV NDraf were prepared by linking the coding regions of wild-type Raf-1 (Bonner et al., 1986 ) and a dominant negative mutant raf cDNA, pmtMNDraf (Schaap et al., 1993) , respectively, to the CMV promoter and were provided by G Thomas. pSG5-3CH134 expressing the ERK-speci®c protein phosphatase MKP-1 (Sun et al., 1993) was provided by N Tonks. pLp85, pLpD85 and pLpDC85 were prepared by linking to the CMV promoter in pcDNA3 (Invitrogen) the following coding regions: the human p85 regulatory subunit of PI 3-kinase (Skolnik et al., 1991) , a dominant negative mutant of p85 that has a deletion of the domain between the two SH2 domains (iSH2) required for the binding to the catalytic subunit p110 (Klippel et al., 1993) , and a mutant p85 that has a C-terminus truncation encompassing both SH2 domains and the iSH2 domain, respectively. pSV-v-src contains the coding region of viral Src linked to the SV40 promoter and was obtained from K Ballmer-Hofer (Piwnica-Worms et al., 1987) .
Transient transfection and analysis of gene expression NIH3T3 cells (0.15610 6 cells/well) were transfected by the calcium phosphate transfection method as described (Besser et al., 1995a) . MDCK cells (0.4610 6 cells/well) were transfected by the liposome-mediated transfection method using DOTAP (Boehringer Mannheim) as described (Besser et al., 1995b) . After 24 h, the cells were harvested in 200 ml luciferase-lysis buer containing 25 mM glycylglycine⋅NaOH, pH 7.8, 1 mM DTT, 15% glycerol, 8 mM MgSO 4 1 mM EDTA and 1% Triton X-100. Total protein (10 mg) was transferred to microtiter plates (Microlite 1; Dynatech) and luciferase activity was measured in a luminometer (MicroLumat LB 96 P; EG&G, Berthold) after injecting 100 ml of luciferin solution containing 25 mM glycylglycine⋅NaOH, pH 7.8, 10 mM MgSO 4 , 1.5 mM ATP and 330 mM luciferin (Chemie Brunschwig AG). The protein concentration was determined using a Micro BCA protein assay system (Pierce).
Abbreviations HGF/SF(-R), hepatocyte growth factor/scatter factor (-receptor); PI 3-kinase, phosphatidylinositol 3-kinase; PLCg, phospholipase C g; SH2, Src homology 2; ERK, extracellular signal regulated kinase; FGF-2, ®broblast growth factor-2; TPA, 12-O-tetradecanoylphorbol-13-acetate; uPA, urokinase-type plasminogen activator; kb, kilobases; bp, base pair(s); MKP-1, ERK phosphatase-1.
